Agios Pharmaceuticals
AGIO
164 hedge funds and large institutions have $2.81B invested in Agios Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 43 increasing their positions, 68 reducing their positions, and 37 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.77% less ownership
Funds ownership: 107.08% → 103.31% (-3.8%)
11% less funds holding
Funds holding: 185 → 164 (-21)
20% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $17.8M
23% less capital invested
Capital invested by funds: $3.63B → $2.81B (-$820M)
37% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 68
51% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$20.4M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$15.7M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$12.4M |
| 4 |
D.E. Shaw & Co
New York
|
+$5.77M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$76.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$59.6M |
| 3 |
JP Morgan Chase
New York
|
-$44.4M |
| 4 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
-$21.4M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$19.1M |
AGIO Hedge Fund Activity: Q3 2021 in Review
164 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2021, worth a combined $2.81B — down 23% from $3.63B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of AGIO and 18 opened new positions — a net loss of 19 holders — while 68 trimmed existing stakes and 43 added.
The largest buyer was State Street, adding an estimated $20.4M. The largest seller was Wellington Management Group, cutting an estimated $76.7M.
- 164 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2021, down from 185 in Q2 2021.
- Funds reported $2.81B of Agios Pharmaceuticals stock for Q3 2021, down 23% quarter-over-quarter.
- 18 funds opened new Agios Pharmaceuticals positions in Q3 2021 and 37 closed out, a net change of -19 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2021 was State Street, an estimated $20.4M added.
- The largest Agios Pharmaceuticals seller in Q3 2021 was Wellington Management Group, an estimated $76.7M sold.
Based on aggregated 13F filings for Q3 2021.